<DOC>
	<DOCNO>NCT03088540</DOCNO>
	<brief_summary>To assess safety efficacy REGN2810 first-line treatment patient advance metastatic NSCLC whose tumor express PD-L1 .</brief_summary>
	<brief_title>Study REGN 2810 Compared Platinum-Based Chemotherapies Participants With Metastatic Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>There option join genomics sub-study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>A patient must meet follow criterion eligible inclusion study : 1 . Patients histologically cytologically document squamous non squamous NSCLC stage IIIB stage IV disease receive prior systemic treatment recurrent metastatic NSCLC 2 . Archival newly obtain formalinfixed tumor tissue metastatic/recurrent site , previously irradiate 3 . Tumor cell express PD L1 specific percentage tumor cell IHC perform central laboratory 4 . At least 1 radiographically measureable lesion per RECIST 1.1 5 . ECOG performance status â‰¤1 6 . Anticipated life expectancy least 3 month 7 . Adequate organ bone marrow function A patient meet follow criterion exclude study : 1 . Patients never smoke , define smoke &lt; 100 cigarette lifetime 2 . Active untreated brain metastasis spinal cord compression 3 . Patients tumor test positive EGFR gene mutation , ALK gene translocation , ROS1 fusions 4 . Encephalitis , meningitis , uncontrolled seizure year prior inform consent 5 . History interstitial lung disease ( eg , idiopathic pulmonary fibrosis , organize pneumonia ) active , noninfectious pneumonitis require immunesuppressive dos glucocorticoid assist management . A history radiation pneumonitis radiation field permit 6 . Patients active , know , suspect autoimmune disease require systemic therapy past 2 year 7 . Patients condition require corticosteroid therapy ( &gt; 10 mg prednisone/day equivalent ) within 14 day randomization 8 . Another malignancy progress require treatment 9 . Known active hepatitis B ( positive result ) hepatitis C ( know positive result ) know quantitative HCV RNA result great low limit detection assay ) 10 . Known history human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome indicate uncontrolled active infection . Patients highly active antiretroviral therapy undetectable RNA level CD4 count 350 permit 11 . Active infection require systemic therapy within 14 day prior randomization 12 . Prior therapy antiPD 1 antiPD L1 13 . Treatmentrelated immunemediated AEs immunemodulatory agent 14 . Receipt investigational drug device within 30 day 15 . Receipt live vaccine within 30 day plan start study medication 16 . Major surgery significant traumatic injury within 4 week prior first dose 17 . Documented allergic acute hypersensitivity reaction attribute antibody treatment 18 . Known allergy doxycycline tetracycline antibiotic 19 . Known psychiatric substance abuse disorder would interfere participation requirement study , include current use illicit drug 20 . Pregnant breastfeed woman 21 . Women childbearing potential unwilling practice highly effective contraception prior initial dose , study , least 6 month last dose 22 . Patients committed institution virtue order issue either judicial administrative authority exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>